Free Trial

Health Sciences Acquisitions Co. 2 (HSAQ) Competitors

Health Sciences Acquisitions Co. 2 logo
$3.22 +0.03 (+0.94%)
As of 07/24/2025

HSAQ vs. INFU, NSPR, CTCX, TMDIF, GBS, RVP, PETV, BTCY, INVO, and TTOO

Should you be buying Health Sciences Acquisitions Co. 2 stock or one of its competitors? The main competitors of Health Sciences Acquisitions Co. 2 include InfuSystem (INFU), InspireMD (NSPR), Carmell (CTCX), Titan Medical (TMDIF), GBS (GBS), Retractable Technologies (RVP), PetVivo (PETV), Biotricity (BTCY), INVO Bioscience (INVO), and T2 Biosystems (TTOO). These companies are all part of the "surgical & medical instruments" industry.

Health Sciences Acquisitions Co. 2 vs. Its Competitors

InfuSystem (NYSE:INFU) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

In the previous week, InfuSystem had 9 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 9 mentions for InfuSystem and 0 mentions for Health Sciences Acquisitions Co. 2. InfuSystem's average media sentiment score of 0.80 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that InfuSystem is being referred to more favorably in the media.

Company Overall Sentiment
InfuSystem Positive
Health Sciences Acquisitions Co. 2 Neutral

InfuSystem has a net margin of 1.12% compared to Health Sciences Acquisitions Co. 2's net margin of 0.00%. InfuSystem's return on equity of 2.78% beat Health Sciences Acquisitions Co. 2's return on equity.

Company Net Margins Return on Equity Return on Assets
InfuSystem1.12% 2.78% 1.41%
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

InfuSystem has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InfuSystem$137.58M0.92$870K$0.1442.93
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A

InfuSystem presently has a consensus target price of $12.50, suggesting a potential upside of 107.99%. Given InfuSystem's stronger consensus rating and higher possible upside, analysts clearly believe InfuSystem is more favorable than Health Sciences Acquisitions Co. 2.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InfuSystem
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
3 Strong Buy rating(s)
4.00
Health Sciences Acquisitions Co. 2
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

71.1% of InfuSystem shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 10.2% of InfuSystem shares are held by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

InfuSystem has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500.

Summary

InfuSystem beats Health Sciences Acquisitions Co. 2 on 11 of the 13 factors compared between the two stocks.

Get Health Sciences Acquisitions Co. 2 News Delivered to You Automatically

Sign up to receive the latest news and ratings for HSAQ and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HSAQ vs. The Competition

MetricHealth Sciences Acquisitions Co. 2Surgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$36.10M$66.04M$5.74B$9.51B
Dividend YieldN/AN/A4.60%3.99%
P/E RatioN/A6.1628.1120.03
Price / SalesN/A139.16461.37103.88
Price / CashN/A18.4136.5559.01
Price / Book-5.197.298.655.90
Net Income-$380K-$25.32M$3.25B$258.66M
7 Day Performance10.27%0.54%4.20%2.23%
1 Month PerformanceN/A3.04%10.82%12.76%
1 Year Performance-60.05%53.10%34.70%19.36%

Health Sciences Acquisitions Co. 2 Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HSAQ
Health Sciences Acquisitions Co. 2
N/A$3.22
+0.9%
N/A-60.0%$36.10MN/A0.004
INFU
InfuSystem
3.3133 of 5 stars
$5.52
-1.6%
$13.00
+135.5%
N/A$116.01M$137.58M92.02410News Coverage
Analyst Forecast
Analyst Revision
NSPR
InspireMD
2.5395 of 5 stars
$2.32
-1.5%
$4.50
+94.4%
-14.4%$70.92M$7.03M-3.0950
CTCX
Carmell
N/A$2.65
-1.3%
N/A+316.0%$55.29M$32.84K0.0014
TMDIF
Titan Medical
N/A$0.33
-8.5%
N/A+979.5%$37.74M$17.63M-0.2650Gap Down
GBS
GBS
N/A$1.77
-3.3%
N/A+46.2%$26.36MN/A-3.167
RVP
Retractable Technologies
1.9705 of 5 stars
$0.68
+1.5%
N/A-35.3%$20.36M$33.75M-1.26240
PETV
PetVivo
N/A$0.75
+0.8%
N/A+29.1%$18.21M$1.05M-1.6720
BTCY
Biotricity
N/A$0.44
+7.9%
N/A-34.7%$11.01M$12.06M-0.4140Analyst Revision
Gap Up
INVO
INVO Bioscience
N/A$0.79
+1.7%
N/AN/A$3.01M$5.77M0.0025Gap Up
TTOO
T2 Biosystems
2.2723 of 5 stars
$0.11
-5.2%
$5.00
+4,445.5%
-99.4%$2.32M$7.68M0.00180Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:HSAQ) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners